Fairvalue-Calculator Fairvalue-Calculator
EN DE

Invivyd, Inc (IVVD) Fair Value & Analysis

Healthcare · US · Market cap $286M

Price$0.9338
Fair Value$0.7200
Upside-22.9%
Quality95/100
Evidence: Low Range $0.4800 – $0.9000

Fair value as of: Jun 25, 2026

Analysis

Invivyd, Inc (IVVD) currently trades at $0.9338, while our model-based Fair Value estimate is $0.7200 — implying the stock looks roughly 22.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, I…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Invivyd, Inc (IVVD) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.7200 versus a price of $0.9338 — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of IVVD?
Our 21-model fair value for Invivyd, Inc is $0.7200 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.9338.
What is the quality score of IVVD?
Invivyd, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.